European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients
Natalia Elliot | August 27, 2024 | News story | Research and Development | J&J, Oncology, chemotherapy, non-small cell lung cancer
Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission (EC) has approved a combined treatment of rybrevant (amivantamab) and chemotherapy (carboplatin and pemerexed) for the treatment of non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR).
Kiran Patel, MD, vice president, Clinical Development, Solid Tumours , Johnson & Johnson Innovative Medicine commented: “Today’s approval marks further positive progress in our mission to transform the treatment landscape for people living with lung cancer.”
The decision comes after the results of the Phase 3 MARIPOSA study were announced. The study evaluated the safety profile and to the efficacy of amivantamab and chemotherapy in patients with locally-advanced or metastatic EGFR ex19del or L858R substitution NSCLC who had disease progression on or after treatment with osimertinib.
The trial met its primary endpoint, reducing the risk of disease progression or death by a significant 52% in comparison to chemotherapy alone. Additionally, amivantamab plus chemotherapy showed an objective response rate (ORR) of 64% , compared to 36%with chemotherapy alone.
Antonio Passaro, MD PhD, medical oncologist, Division of Thoracic Oncology at the European Institute of Oncology in Milan, Italy stated: “The addition of the bispecific antibody amivantamab to chemotherapy offers an important new treatment option for patients with EGFR ex19del or L858R mutations, progressing on or after osimertinib. In this setting, this combination set the new landmark for overall response rate and reduced the risk of disease progression or death by more than half compared to standard chemotherapy alone. It also demonstrated significant improvements in intracranial progression-free survival.”
Natalia Elliot
Related Content
HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …
FDA grants accelerated approval for advanced non-small cell lung cancer treatment
The US Food and Drug Administration (FDA) has granted accelerated approval to Dizal Therapeutic’s Zegfrovy …
Combination first-in-line treatment approved for patients with non-small cell lung cancer
Johnson & Johnson Innovative Medicine have announced that the European Commission (EC) has approved a …
